BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
Go back to BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis| (NASDAQ: BYSI) | Delayed: 0.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.50 | 52 Week High | $ | |||
| Open | $0.50 | 52 Week Low | $ | |||
| Day High | $0.50 | P/E | N/A | |||
| Day Low | $0.50 | EPS | $ | |||
| Volume | 117 | |||||



